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Background: Depression-related mortality and morbidity pose growing public health
burdens worldwide. Although the therapeutic effect of exogenous melatonin on
depression has been investigated, findings remain inconsistent. We conducted this
systematic review and meta-analysis to clarify the effectiveness of melatonin in the
treatment of depression, including primary and secondary depression symptoms.
Methods: We searched the online databases of PubMed, EMBASE, and the Cochrane
Library for original studies published up to May 2021. We used STATA 14.0 software to
synthesize the results of included studies. To evaluate the effectiveness of melatonin, we
calculated the standardized mean differences (SMDs) and 95% confidence intervals (CIs)
of depression scores between the melatonin and placebo groups.
Results: Our literature search returned 754 publications, among which 19 studies with
1,178 patients (715 women, 463 men; mean age: 56.77 years) met inclusion criteria.
Melatonin dosages ranged from 2 to 25 mg per day; treatment durations were between
10 days and 3.5 years. Our synthesized results showed that melatonin was not found
significantly beneficial for alleviating depressive symptoms (SMD = −0.17, 95% CI =
[−0.38, 0.05]). Subgroup analysis demonstrated that the decrease in depression scores
measured with the Beck Depression Inventory (BDI) was significant (SMD = −0.52, 95%
CI = [−0.73, −0.31]).
Conclusions: There is very limited evidence for effects of melatonin on depression.
Keywords: melatonin, depression, depressive symptoms, therapeutic effect, systematic review
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INTRODUCTION

(4) the study involved the diagnosis and/or measurement of
depression; (5) the severity of depression was rated by a selfor clinician-administered questionnaire; (6) the mean severity
of depressive symptoms was compared between melatonin and
placebo groups; (7) the dose and mode of administration were
reported; and (8) the study was published in English.
Exclusion criteria were as follows: (1) melatonin was not
given as an intervention; (2) no scores on depressive symptoms
were reported in the melatonin and placebo groups; and (3) the
effect of melatonin or placebo was not reported separately from
other interventions.

Depression, one of the most common psychiatric disorders,
contributes to morbidity and mortality in adults and adolescents
worldwide (1). The World Health Organization reported that
the number of people suffering from depression increased
by more than 18% from 2005 to 2015 (2). Depression is
considered as a heterogeneous disease on account of complex
pathological mechanisms and multiple etiologies (1). Currently,
the efficacy for depression therapy is limited due to the
need for long-term treatment and variation in symptom
presentation (2). Antidepressant medication lacks uniform
effectiveness. The large treatment-refractory population indicates
the need to explore additional therapeutic agents, such as
novel antidepressive treatments that have fewer side effects
(3, 4). Nevertheless, successful treatment is believed to enable
a dramatic improvement in patients’ overall functioning and
quality of life (5).
Melatonin, also known as 5-methoxy-N-acetyltryptamine, is
a pleiotropic neurohormone secreted by the pineal gland at low
levels during the daytime and high levels at night (6). Disorders of
melatonin secretion were found to be historically associated with
depression; however, when used as a therapy for this condition,
exogenous melatonin is thought to function by normalizing
patients’ disrupted circadian architecture via binding to two
receptors (MT1 and MT2 ) in the suprachiasmatic nucleus and
other parts of the brain (7–10).
At present, studies exploring the therapeutic impact of
exogenous melatonin on depression treatment have shown
inconsistent results (11–16). In 2014, a systematic review
and meta-analysis revealed that exogenous melatonin had no
therapeutic or prophylactic effect on depression (17). Another
systematic review involving three trials reported a non-significant
effect of melatonin on treating depressive episodes (18). However,
five newly published randomized controlled trials (RCTs)
demonstrated the beneficial effects of melatonin in depression
treatment (14, 19–22). In these five studies, melatonin was treated
for 12 weeks, and the participants were with moderate to severe
depression. While the previously published studies that did
not testify the effectiveness of melatonin involved participants
with mild depression symptom. Here, we report a systematic
review and meta-analysis and provide updated findings on the
effectiveness of melatonin on depression treatment including
primary and secondary depression symptoms.

Search Strategies and Study Screening
We searched PubMed, EMBASE, and the Cochrane Library for
trials published up to May 15, 2021.
The terms “melatonin, depression, depressive disorders, mood
disorders, depressive symptoms, treat∗ , effect∗ , and therapeutics”
were used for the literature search (17).
To improve the search strategy, we used restriction options
in accordance with the population, intervention, comparison,
and outcomes principle: study participants were selected from
an adult population; the intervention agent was melatonin; the
comparison agent was placebo; and the outcome was the relevant
score for depressive symptoms as measured by investigators.
Specific search parameters were as follows: (1) PubMed: clinical
trial, RCT, humans, adults, English language; (2) EMBASE:
controlled clinical trial, RCT, clinical study, humans, 18+ years,
English language; (3) the Cochrane Library: no restrictions.
Two authors (CL and DaM) independently reviewed the
literature to screen original studies by reading the title, abstract,
and/or full text of each. References cited in the included
studies were also screened for eligibility. All inconsistencies and
disagreements were resolved through discussion with a third
author (ML).

Data Collection
Two authors (CL and DaM) extracted data from the selected
studies, such as the study characteristics, intervention, primary
outcomes, measurement instruments, and adverse events. For
studies that provided the mean and standard deviation (SD) of
depression scores, we recorded summary data directly; otherwise,
we calculated summary data using statistical approaches. Of
studies in which the 95% confidence interval (CI) was reported,
the SD was calculated using the following equation:
SD =

METHODS

n × (upper limit − lower limit)/3.92

In studies in which the median and interquartile range (IQR)
were reported, the mean and SD were computed as follows (23):

Our study was conducted in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(Supplementary Table S1 and Supplementary Box 1).

mean ≈ median

Inclusion and Exclusion Criteria

SD ≈ Norm IQR = (P75 − P25 ) × 0.7413

Original studies that met the following criteria were included in
our meta-analysis: (1) study participants were adults (aged ≥ 18
years); (2) the effect of melatonin on remission of depression
was investigated among participants with depressive symptoms;
(3) RCTs or randomized crossover trials were performed;
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Statistical Analysis
The meta-analysis was conducted with STATA 14.0 software
(Stata Corp, College Station, TX, USA). The standardized mean
difference (SMD) and 95% CI were synthesized to evaluate
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FIGURE 1 | Flow diagram of literature screening.

the difference in depression scores between the melatonin
and placebo groups. Statistical heterogeneity was examined
on the basis of Cochran’s Q test and the I 2 statistic. When
p < 0.10 and I 2 > 50%, original studies were regarded
as demonstrating heterogeneity, and a random-effect model
meta-analysis was undertaken; otherwise, a fixed-effect model
meta-analysis was carried out. Subgroup analyses were also
performed on the basis of depression scales, melatonin dosage,
and/or treatment duration. To assess the robustness of the
meta-analysis, sensitivity analysis was conducted by removing
each original study one at a time. Publication bias was identified

Frontiers in Psychiatry | www.frontiersin.org

through funnel plot analysis along with Egger’s regression
asymmetry test. In terms of the quality of each study, the risk
of bias was assessed via Review Manager Version 5.4 (Cochrane
Collaboration, Oxford, UK), including seven domains with each
domain containing three types of risk (23).

RESULTS
Literature Search
The literature search and screening process is depicted in
Figure 1. Our initial search returned 754 records, among which
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Country

N. participants Age
(N. loss to
follow-up)

Chojnacki et al.
(24)

Poland

64 (4)

MEL: 35.6 ± 11.4 BDI

F: 38, M: 22

PLC: 33.9 ± 11.7

60 (6)

MEL: 42.5 ± 8.0

M: 60 (6)

PLC: 42.7 ± 9.9

60 (9)

MEL: 64.4 ± 8.2

F: 19, M:32

PLC: 66.3 ± 9.3

60 (2)

MEL: 26.5 ± 3.5

F: 60 (2)

PLC: 26.0 ± 3.3

60 (7)

MEL: 65.6 ± 13.1 BDI

F: 15, M: 38

PLC: 64.1 ± 8.2

33 (2)

MEL: 38.1 ± 11.6 BDI and
HDRS-21

F: 27, M: 4

PLC: 42.0 ± 12.6

Ghaderi et al.
(19)

Daneshvar
Kakhaki et al.
(21)

4

Shabani et al.
(20)

Iran

Iran

Iran

OstadmohammadiFinland
et al. (22)

Serfaty et al. (15) UK

Scales of
depression

BDI

BDI

BDI

Comorbidities
Basic
medicine/other
treatment

Mesalazine

Ulcerative colitis No

MMT patients
Methadone
maintenance
treatment (MMT)

Not available

Not available

None

March 2022 | Volume 13 | Article 737972

Treatment as
usual

Primary
depression

Parkinson’s
disease

No

No

Polycystic ovary No
syndrome

Diabetic
Hemodialysis

No

Major depressive Yes
disorder

Melatonin and
placebo
administration

Treatment
duration and
depression
score after
treatment

Adverse events

5 mg melatonin or
placebo daily at
bedtime for 3 months

12 weeks:
16.7 ± 3.5 (MEL)

Headaches

12 weeks:
17.7 ± 2.5 (PLC)

10 mg melatonin or
12 weeks:
placebo once a day, 1 19.5 ± 9.1 (MEL)
hour before bedtime for
12 weeks
12 weeks:
23.3 ± 8.8 (PLC)

10 mg melatonin or
12 weeks:
placebo once a day, 1 h 18.7 ± 4.1 (MEL)
before bedtime for 12
weeks
12 weeks:
21.4 ± 4.9 (PLC)

10 mg melatonin or
12 weeks:
placebo once a day, 1 h 16.9 ± 3.6 (MEL)
before bedtime for 12
weeks
12 weeks:
20.6 ± 5.1 (PLC)

5 mg melatonin or
12 weeks:
placebo twice a day, 1 21.9 ± 3.9 (MEL)
hour before bedtime for
12 weeks

6 mg melatonin or
placebo once a day at
bedtime over 4 weeks

Headache, daytime
sleepiness, and
dizziness

Headache and daytime
sleepiness

Not available

None

12 weeks:
24.8 ± 5.0 (PLC)

BDI: 5 weeks:
Poor sleep, vivid
18.5 ± 11.6 (MEL) dreams, day time
sleepiness and fuzzy
feeling
5 weeks:
21.7 ± 9.6 (PLC)

HDRS-21 items: 4
weeks: 13.3 ± 6.7
(MEL)
4 weeks:
14.7 ± 5.8 (PLC)
(Continued)
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TABLE 1 | Characteristics of the included studies.

Author

Country

Palmer et al. (14) Brazil

Roostaei et al.
(25)

Chen et al. (26)

Peles et al. (32)

Iran

USA

Israel

Primary
depression

Melatonin and
placebo
administration

36 (0)

MEL:
54.24 ± 10.59

BDI

Breast cancer
Adjuvant
chemotherapy
for breast cancer

No

10 days:
None
20 mg melatonin or
placebo once a day, 1 h 6.71 ± 4.57 (MEL)
before bedtime

F: 36 (0)

PLC: 54.11 ± 9.15

26 (1)

MEL: 33.3 ± 7.6

F: 21, M: 4

PLC: 34.5 ± 8.2

95 (9)

MEL: Mean 59
(range 48–80)

F: 95 (9)

PLC: Mean 59
(range 38–71)

80 (19)

42.6 ± 1.2

5

Comorbidities
Basic
medicine/other
treatment

10 days:
14.56 ± 7.76
(PLC)
BDI

CES-D

CES-D

Once weekly
interferon beta

Not available

Methadone

Multiple sclerosis No

Postmenopausal No
breast cancer

Sleep
disturbances

No

33 (1)

37 ± 11

HADS-D

None

Traumatic brain
injury

No

3 mg melatonin or
12 months:
None
placebo once a day for 19.12 ± 8.6 (MEL)
12 months
12 months:
14.3 ± 7.8 (MEL)

12 weeks:
3 mg melatonin or
placebo once a day for 6.5 ± 4.6 (MEL)
4 months
12 weeks:
6.0 ± 5.4 (PLC)

6 weeks:
5 mg melatonin or
placebo once a day for 1.3 ± 0.1 (MEL)
6 weeks one arm,
1-week washout, 6
weeks other arm

Singapore

24 (7)

F: 24 (7)

2 mg melatonin or
placebo once a day
before bedtime for 4
weeks one arm,
48-hour washout
period, 4 weeks other
arm

None

Not available

6 weeks:
1.2 ± 0.1 (PLC)

None
4 weeks: 8.53
(95% CI:
6.93–10.13) (MEL)

4 weeks: 8.34
(95% CI:
6.75–9.94) (PLC)
Mean 41.2

HADS-D

None

Irritable bowel
syndrome

No

8 weeks:
3 mg melatonin or
placebo once a day for 5.4 ± 2.6 (MEL)
8 weeks one arm,
4-week washout
period, 8 weeks other
arm

Daytime sleepiness

8 weeks:
5.3 ± 2.8 (PLC)
(Continued)
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F: 11, M: 22

Lu et al. (34)

Adverse events

Scales of
depression

F: 24, M: 56
Grima et al. (33) Australia

Treatment
duration and
depression
score after
treatment

N. participants Age
(N. loss to
follow-up)

Li et al.
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TABLE 1 | Continued
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TABLE 1 | Continued
Author

Country

N. participants Age
(N. loss to
follow-up)

Song et al. (27)

Singapore

42 (2)

MEL: Mean 27.15 HADS-D
(SE 1.95)

F:24, M: 16

PLC: Mean 27.70
(SE 2.45)

252 (15)

MEL:
62.90 ± 11.32

F: 56, M: 196

PLC:
62.10 ± 10.81

Madsen et al.
(16)

Denmark

Scales of
depression

HADS-D and
MDI

Adverse events

Comorbidities
Basic
medicine/other
treatment

Primary
depression

Melatonin and
placebo
administration

Treatment
duration and
depression
score after
treatment

None

No

3 mg melatonin or
placebo daily at
bedtime for 2 weeks

2 weeks:
Not available
4.80 ± 4.07 (MEL)

Not available

Irritable bowel
syndrome with
sleep
disturbances

Acute coronary
syndrome

No

2 weeks:
2.85 ± 2.15 (PLC)

25 mg melatonin or
HADS-D 12
Altered bowel habits,
placebo daily 1 h before weeks: 1.19 (95% Tachycardia, Dizziness
bedtime for 12 weeks CI: 0.80–1.57)
(MEL)
12 weeks: 1.48
(95% CI:
1.09–1.88) (PLC)
MDI

6

2 weeks: 5.95
(95% CI:
5.02–6.87) (MEL)
2 weeks: 5.10
(95% CI:
4.30–5.80) (PLC)
Hansen et al.
(28)

USA

Garzon et al. (35) Spain

Mexico

MEL: Mean 51
(IQR 46–66)

F: 54 (8)

PLC: Mean 60
(IQR 49–68)

22 (4)

F: Mean 74.3

F: 15, M: 7

M: Mean 75.8

40 (9)

MEL: 82.2 ± 5.8

F: 24, M: 7

PLC: 83.1 ± 7.4

MDI

After surgery

Breast cancer

No

6 mg melatonin or
2 weeks: 6 (4–12)
placebo once a day for (IQR) (MEL)
3 months (2 weeks
were included)

Dizziness, headache,
and paresthesia in the
mouth region, arms, or
legs

2 weeks: 10
(5.5–19.75) (IQR)
(PLC)
GDS

GDS

Hypnotics (n =
14)

None

Sleep disorder

Mild–moderate
dementia

No

No

8 weeks:
None
5 mg melatonin or
5.61 ± 1.15 (MEL)
placebo daily at
bedtime for 8 weeks, 2
weeks washout, then
crossover 8 weeks
8 weeks:
7.06 ± 1.16 (PLC)

5 mg melatonin or
8 weeks:
placebo every night for 4.9 ± 3.6 (MEL)
8 weeks

no serious adverse
events

8 weeks: 4 ± 1.7
(PLC)
(Continued)
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MoralesDelgado et al.
(31)

54 (8)
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TABLE 1 | Continued
Treatment
duration and
depression
score after
treatment

Author

Country

N. participants Age
(N. loss to
follow-up)

Scales of
depression

Comorbidities
Basic
medicine/other
treatment

Primary
depression

Melatonin and
placebo
administration

Riemersma-van
der Lek et al.
(29)

Netherlands

189 (0)

CSDD

Bright light

No

2.5 mg melatonin or
6 weeks:
placebo daily 1 h before 7.5 ± 6.2 (MEL)
bedtime for maximum
3.5 years

85.8 ± 5.5

Dementia

F: 170, M: 19
Leppämäki et al. Finland
(30)

58 (5)

MEL: 36.0 ± 9.5

F: 44, M: 14

PLC: 42.6 ± 10.8

ATYP

None

Yes
Subsyndromal
seasonal
affective disorder
and/or weatherassociated
syndrome

2 mg melatonin or
placebo daily 1–2 h
before a desired
bedtime for 3 weeks

6 weeks:
7.8 ± 5.2 (PLC)

3 weeks:
1.8 ± 2.8 (MEL)

Adverse events

None

Headaches

3 weeks:
1.2 ± 2.6 (PLC)

7

CI, confidence interval; MEL, melatonin; PLC, placebo; M, male; F, female; IQR, interquartile range; SE, standard error; BDI, Beck Depression Inventory; HDRS-21, 21-item Hamilton Depression Rating Scale; CES-D, Center for
Epidemiological Studies Depression Scale; HADS-D, the Hospital Anxiety and Depression Scale; MDI, Major Depression Inventory; GDS, Yesavage Geriatric Depression Scale; CSDD, Cornell Scale for Depression in Dementia; ATYP,
the 8-item addendum of the Structured Interview Guide for the Hamilton Depression Rating Scale–Seasonal Affective Disorders Version Self-Rating Format.
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FIGURE 2 | Meta-analysis on therapeutic effect of melatonin depression measured by eight scales. SMD, standardized mean difference; CI, confidence interval.

in the original studies, ranging from 17 to 237 patients
per trial. The duration of melatonin treatment was from
10 days to 3.5 years, and the melatonin dosage ranged
from 2 to 25 mg per day. Two melatonin formulations are
available: slow- or fast-release. Individuals in three studies
were administered slow-release melatonin (15, 30, 33).
Most subjects suffered secondary depression syndrome
stemming from other psychiatric or physical disorders
rather than primary depression. With regard to depression
measurement, eight scales were employed to quantify the
severity of depressive symptoms: the Beck Depression
Inventory (BDI); Hospital Anxiety and Depression Scale
(HADS-D); Center for Epidemiologic Studies Depression
(CES-D); Major Depression Inventory (MDI); 21-item
Hamilton Depression Rating Scale (HDRS-21); Yesavage
Geriatric Depression Scale (GDS); Cornell Scale for Depression
in Dementia (CSDD); and the 8-item addendum of the
Structured Interview Guide for the Hamilton Depression
Rating Scale–Seasonal Affective Disorders Version Self-Rating
Format (ATYP).

239 studies were removed due to being duplicates between
databases. Upon reviewing each source’s title and/or abstract, 59
studies were excluded for the following reasons: (1) irrelevance
to melatonin or depression/depressive symptoms (n = 22); or
(2) study in children (n = 37). Of the 456 full-text studies
first reviewed, 437 were excluded for the following reasons:
(1) depression was not assessed quantitatively (n = 97); (2)
melatonin was not given to participants (n = 194); (3) lack
of placebo control (n = 24); (4) melatonin was not solely
used (n = 36); (5) studies were not RCTs or randomized
crossover trials (n = 53); (6) no data were available (n = 7);
(7) study protocols (n = 23); (8) publications in a language
other than English (n = 3). Consequently, 19 studies were
included in the meta-analysis, among which 15 were RCTs
(14–16, 19–22, 24–31) and four were randomized crossover
trials (32–35).

Characteristics of Included Studies
As shown in Table 1, a total of 1,178 participants (715
women, 463 men; mean age: 56.77 years) were involved

Frontiers in Psychiatry | www.frontiersin.org
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Effect of Melatonin on Depressive
Symptoms as Measured by BDI

TABLE 2 | Subgroup analyses on the effect of melatonin on depressive
symptoms.
Subgroup
Dosages

SMD (95% CI)
2 mg/day
2.5 mg/day
3 mg/day
5 mg/day
6 mg/day
10 mg/day
20 mg/day
25 mg/day

Treatment durations

1.5 weeks
2 weeks
3 weeks
4 weeks
5 weeks
6 weeks
8 weeks
12 weeks
48 weeks

Depression scales

BDI
HADS-D
CES-D
MDI
GDS
CSDD
ATYP
HDRS-21

0.12 (−0.25, 0.49)

0.536

−0.05 (−0.46, 0.36)

0.803

0.26 (−0.03, 0.55)

0.084

−0.05 (−0.97, 0.87)

0.909

−0.33 (−0.68, 0.02)

−0.70 (−0.98, −0.43)

0.062
<0.001

−1.23 (−1.95, −0.52)

0.001

0.03 (−0.29, 0.34)

0.896

−1.23 (−1.95, −0.52)

0.001

0.10 (−0.40, 0.61)

0.683

0.22 (−0.35, 0.79)

0.449

−0.08 (−0.44, 0.29)

−0.30 (−1.01, 0.41)

0.680
0.404

0.46 (−0.57, 1.49)

0.382

−0.30 (−1.23, 0.64)

0.533

−0.41 (−0.69, −0.13)

0.004

0.59 (−0.22, 1.39)

0.153

−0.52 (−0.73, −0.31)

<0.001

−0.01 (−0.22, 0.19)
0.53 (−0.35, 1.42)

0.235
0.777

−0.47 (−2.01, 1.07)

Effect of Melatonin on Depressive
Symptoms as Measured by HADS-D
Four original studies used the HADS-D to evaluate depressive
symptoms. As illustrated in Supplementary Figure S4 and
Table 2, no significant decrease in HADS-D scores was
observed between the melatonin and placebo groups (SMD
= −0.01, 95% CI = [−0.22, 0.19]). Similar results were
found in subgroup analysis using the treatment regimen of
3 mg/day melatonin (SMD = 0.33, 95% CI = [−0.13, 0.80])
(Supplementary Figure S5). No significant heterogeneity was
observed across the above studies.

0.900

−0.09 (−0.74, 0.56)

−0.05 (−0.46, 0.36)

Eight studies reported depression severity measured using the
BDI. As displayed in Supplementary Figure S3A and Table 2,
a significant difference in BDI scores was identified between
melatonin and placebo groups (SMD = −0.52, 95% CI = [−0.73,
−0.31]) without significant bias induced by heterogeneity
(I 2 = 49.0%, p = 0.056). Subgroup analysis revealed that
the SMD of BDI scores was −0.56 (95% CI = [−0.80,
−0.32]) after 12 weeks of melatonin treatment compared with
placebo (Supplementary Figure S3B and Table 2). Collectively,
the results of three studies in which participants were treated with
10 mg of melatonin per day for 12 weeks showed that melatonin
significantly alleviated depressive symptoms (SMD = −0.63, 95%
CI = [−0.90, −0.35]) (Supplementary Figure S3C and Table 2).
The above data indicate that the most effective strategy was to
treat melatonin for 12 weeks with a daily dose of 10 mg.

P

0.551
0.803

0.22 (−0.35, 0.79)

0.449

−0.22 (−0.77, 0.32)

0.424

SMD, standardized mean difference; CI, confidence interval; BDI, Beck Depression
Inventory; HADS-D, the Hospital Anxiety and Depression Scale; CES-D, Center for
Epidemiological Studies Depression Scale; MDI, Major Depression Inventory; GDS,
Yesavage Geriatric Depression Scale; CSDD, Cornell Scale for Depression in Dementia;
ATYP, the 8-item addendum of the Structured Interview Guide for the Hamilton Depression
Rating Scale–Seasonal Affective Disorders Version Self-Rating Format; HDRS-21, 21-item
Hamilton Depression Rating Scale.

Effect of Melatonin on Depressive
Symptoms as Measured by CES-D
We synthesized two studies that measured depressive symptoms
with the CES-D. As shown in Supplementary Figure S6 and
Table 2, the pooled result reflected no significant effect of
melatonin on CES-D scores (SMD = 0.53, 95% CI = [−0.35,
1.42]) with significant heterogeneity (I 2 = 85.1%, p = 0.010).

Effect of Melatonin on Depressive
Symptoms

Effect of Melatonin on Depressive
Symptoms as Measured by MDI

As shown in Figure 2 and Table 2, no significant results were
observed in the overall meta-analysis of the effect of melatonin on
depression treatment (SMD = −0.17, 95% CI = [−0.38, 0.05]).
Significant heterogeneity was identified across the included
studies (I2 = 73.6%, p < 0.001). Furthermore, subgroup analyses
on melatonin dosages and treatment durations were conducted,
in which melatonin was shown to be significantly effective at the
dosages of 10 mg/day (SMD = −0.70, 95% CI = [−0.98, −0.43])
and 20 mg/day (SMD = −1.23, 95% CI = [−1.95, −0.52])
(Supplementary Figure S1 and Table 2). However, no significant
results were observed at other dosages, including 2, 2.5, 3, 5, 6,
and 25 mg/day. As depicted in Supplementary Figure S2 and
Table 2, a significance decrease in depression scores was found
after 12 weeks of melatonin treatment (SMD = −0.41, 95% CI
= [−0.69, −0.13]). Meanwhile, no positive results were observed
after 1.5, 2, 3, 4, 5, 6, 8, and 48 weeks treatment.
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Two original studies used the MDI to evaluate depression
severity. As listed in Supplementary Figure S7 and Table 2, no
significant difference was observed between the melatonin and
placebo groups (SMD = −0.09, 95% CI = [−0.74, 0.56]) with
significant heterogeneity (I 2 = 76.0%, p = 0.041).

Effect of Melatonin on Depressive
Symptoms as Measured by GDS
We included two studies that reported depression severity with
the GDS. As Supplementary Figure S8 and Table 2 indicate, the
pooled result demonstrated no significant effect of melatonin
on GDS scores (SMD = −0.47, 95% CI = [−2.01, 1.07]) with
significant heterogeneity (I 2 = 89.3%, p = 0.002).
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FIGURE 3 | (A,B) Risk of bias graph and summary. Green means low risk of bias; yellow means unclear risk of bias; red means high risk of bias.

Effect of Melatonin on Depressive
Symptoms as Measured by HDRS-21,
CSDD, or ATYP

low risk of bias while six had an unclear risk. Only one study
had a high risk of attrition bias that might be caused by the
uneven frequencies of participants lost to follow-up between the
intervention and control groups. Eleven studies had a low bias on
selective reporting (i.e., reporting bias) because these studies were
carried out in accordance with the registered protocol; the other
eight studies did not indicate the clinical trial registry in detail.

Regarding other scales, only one study reported depressive
symptoms with the HDRS-21, CSDD, or ATYP. As such, no
meta-analysis was conducted.

Evaluation of Risk of Bias According to the
Cochrane Risk of Bias Tool

Publication Bias and Sensitivity Analysis

The risk of bias among included studies is presented in Figure 3.
All studies had a low risk of bias on random sequence generation
(i.e., selection bias) and blinding of participants and personnel
(i.e., performance bias). The random assignment method and
generation of random sequences were clarified. The application
of blinding was described as well. Thirteen studies involved a low
risk of bias on allocation concealment (i.e., selection bias); six
other studies had an unclear risk. As for detection bias induced
by a lack of blinding in outcome assessment, 13 studies had a

A funnel plot and Egger’s test were used to confirm whether
the meta-analysis results were influenced by publication bias.
As presented in Figure 4, Supplementary Figures S9, S10, no
significant bias emerged in meta-analysis of the combination of
eight scales (PEgger′ s = 0.278), the BDI (PEgger′ s = 0.459), and
the HADS-D (PEgger′ s = 0.219). Sensitivity analyses showed no
substantial changes in the combined results when each study
was removed in turn, highlighting the stability of our metaanalysis (Supplementary Figures S11–S13). Tests for the CES-D,
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FIGURE 4 | Funnel plot analysis. SMD, standardized mean difference; SE, standard error.

depressive symptoms were measured with the HADS-D, CES-D,
MDI, or GDS.
Depressive disorders are characterized by psychological,
behavioral, and physiological changes, affecting 17–20% of the
population globally (36). Circadian rhythm disturbance is a
major feature of depressive symptoms: 70% of patients with
severe depression suffer from sleep disturbances (37, 38). The
association between depression and desynchronized circadian
rhythms suggests that agents improving circadian rhythms may
contribute to relieving depression. Melatonin, an endogenous
hormone mainly synthesized in the pineal gland, plays a key
role in synchronizing circadian rhythms. By binding to two
receptors (MT1 and MT2 ) in the suprachiasmatic nucleus,
melatonin regulates the expression of clock genes, resulting
in a chronobiotic effect (26, 37, 39). Patients with depression
have shown reduced peak values of plasma melatonin at night
with a disordered rhythm phase (40). Exogenous melatonin
also has an effect on synchronizing rhythms; it is thus
thought to hold promise for treating depressive symptoms (38,
41–43). Furthermore, sleep disorders and biological rhythm
abnormalities among individuals with depression are generally
affected by sex. Women are twice as likely as men to suffer from
depression due to the influence of gonadal hormones, which
are involved in sleep regulation and human neurotransmitter
regulation (44).

MDI, and GDS were not carried out due to the small number of
included studies.

Adverse Effects of Melatonin
Eight of 19 studies (15, 16, 19, 21, 24, 28, 30, 34) discussed
adverse events associated with melatonin administration (e.g.,
headache, daytime sleepiness, dizziness, poor sleep, insomnia,
a fuzzy feeling, altered bowel habits, and tachycardia), among
which six reported data on adverse events (15, 16, 19, 21, 28, 30).
The average adverse event rate was 16.41% in the melatonin
group and 14.73% in the placebo group. Meta-analysis showed
no significant difference in adverse events between the melatonin
and placebo groups (odds ratio = 1.52, 95% CI = [0.80, 2.91], p
= 0.135) (Supplementary Figure S14).

DISCUSSION
Our systematic review and meta-analysis demonstrated that
melatonin was not significantly effective for alleviating depressive
symptoms. Although statistically positive results were observed
at the dosages of 10 and 20 mg/day, there was very limited
evidence for effects of melatonin on depression. Eight scales were
involved in the measurement of depressive symptoms, among
which the effect of melatonin was significant when the BDI
was used. However, no significant effects were identified when
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inconsistent outcomes between studies. Second, the number
of studies included in our meta-analysis was small and might
restrict the generalizability of our findings. Differences in
melatonin dosage, treatment duration, and baseline treatment
influenced the consolidation of our results. Finally, on the basis
of studies included in meta-analysis, we cannot identify the
specific type of depression on which melatonin may be effective
than others.

No biomarkers have yet been identified for the evaluation
of depression; rather, some scales and questionnaires have been
developed. The BDI is commonly used and consists of 21 items
to assess cognitive, affective, behavioral, and somatic symptoms
of depression (45, 46). And studies found that exogenous
melatonin could lead to modulation in specific physiological
functions like control of human mood, behavior, cognition, and
sleep regulation by activating membrane MT1 /MT2 melatonin
receptors (47–49). In practice, the BDI is used not only to
assess depression in psychiatric patients but also to screen for
depressive symptoms in various patient groups (50, 51), and most
participants in this meta-analysis suffered secondary depression
from different diseases. Moreover, the BDI provides information
on a relatively wide range of levels of depression, and is typically
considered a standard tool for depression measurement with
high accuracy and efficiency (45, 52). In terms of other scales,
the HADS-D consists of seven questions and is often used with
patients with moderate depression (53, 54). The HADS-D is
designed to evaluate the anxiety and depressive symptoms of
patients without physical symptoms (e.g., sleep disorders) (55).
However, this scale provides less information than others (45). By
contrast, the 10-item MDI is more accurate for assessing major
(i.e., moderate to severe) depression (56). The CES-D, composed
of 20 items, is also used in the general population and primary
healthcare institutions (57). Yet, the CES-D is considered more
appropriate for evaluating general distress than depression (58).
The GDS is a self-rated scale used primarily to assess depression
in older adults (35). In our sample, the effect of melatonin
was found statistically positive when using the BDI, but not
significant when using the other four depression scales (i.e.,
HADS-D, CES-D, MDI, and GDS).
As a medical sleep aid, a single dose of 1–10 mg of melatonin
has is considered standard, but the optimal dose for depression
is not yet known (59). Based on our findings, the dose of 10
mg/day might work more efficiently. However, no significant
results were observed at other dosages, including 2, 2.5, 3, 5, 6,
and 25 mg/day. In addition, studies have reported that 10 mg per
day is a balanced option considering that melatonin is a safe, nontoxic drug with minor adverse events compared to placebo in
long-term treatment (15, 16). With regard to treatment duration,
no consistent program has been established for psychiatric use
(60). Our subgroup analysis implied that 12-week treatment was
more effective in alleviating depression, in line with the duration
for melatonin receptor agonists agomelatine and ramelteon (61–
63). However, no significant results were observed after 1.5, 2, 3,
4, 5, 6, 8, and 48 weeks treatment. This indicated that there is very
limited evidence for effects of melatonin on depression.
No obvious side effects of melatonin were found in all original
studies included in this systematic review. Some studies also
showed that melatonin had no side effects in the short term and
had mild side effects in the long term (59, 64).

CONCLUSIONS
In conclusion, no sufficient results were obtained to evidence
the effects of melatonin on depression. Melatonin might have no
potential therapeutic effect on depression.
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Limitations

The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fpsyt.
2022.737972/full#supplementary-material

Some limitations should be noted in our study. First, eight
scales were used to measure depressive symptoms, which
led to variation. Differences in these scales, as well as in
participants’ demographics and comorbidity, likely resulted in
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Supplementary Figure S1 | Subgroup analysis on dosage. SMD, standardized
mean difference; CI, confidence interval.
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Supplementary Figure S8 | Meta-analysis on GDS score. GDS, Yesavage
Geriatric Depression Scale; SMD, standardized mean difference; CI, confidence
interval.

Supplementary Figure S2 | Subgroup analysis on treatment duration. SMD,
standardized mean difference; CI, confidence interval.
Supplementary Figure S3 | Meta-analysis of effect of melatonin on depression
measured by BDI score. (A) Overall meta-analysis; (B) subgroup analysis of
studies treated for 12 weeks by all dosages of melatonin; (C) subgroup analysis of
studies treated for 12 weeks by 10 mg/day melatonin; BDI, Beck Depression
Inventory; SMD, standardized mean difference; CI, confidence interval.

Supplementary Figure S9 | Funnel plot analysis on BDI score. SMD,
standardized mean difference; SE, standard error.
Supplementary Figure S10 | Funnel plot analysis on HADS-D score. SMD,
standardized mean difference; SE, standard error.

Supplementary Figure S4 | Meta-analysis of effect of melatonin on depression
measured by HADS-D score. HADS-D, the Hospital Anxiety and Depression
Scale; SMD, standardized mean difference; CI, confidence interval.

Supplementary Figure S11 | Sensitivity analysis on all scales.

Supplementary Figure S5 | Subgroup meta-analysis on HADS-D score within
patients treated by 3 mg/day melatonin. HADS-D, the Hospital Anxiety and
Depression Scale; SMD, standardized mean difference; CI, confidence interval.

Supplementary Figure S13 | Sensitivity analysis on HADS-D score.

Supplementary Figure S12 | Sensitivity analysis on BDI score.

Supplementary Figure S14 | Adverse event analysis. OR, Odds Ratio; CI,
confidence interval.

Supplementary Figure S6 | Meta-analysis on CES-D score. CES-D, Center for
Epidemiological Studies Depression Scale; SMD, standardized mean difference;
CI, confidence interval.

Supplementary Table S1 | Checklist of the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA). Y, the item was reported in
article; N, the item was not reported.

Supplementary Figure S7 | Meta-analysis on MDI score. MDI, Major Depression
Inventory; SMD, standardized mean difference; CI, confidence interval.

Supplementary Box 1 | Study protocol.
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